BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 16287099)

  • 21. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
    Shi RX; Ong CN; Shen HM
    Cancer Res; 2005 Sep; 65(17):7815-23. PubMed ID: 16140950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-gingerol in cervical cancer cells.
    Rastogi N; Duggal S; Singh SK; Porwal K; Srivastava VK; Maurya R; Bhatt ML; Mishra DP
    Oncotarget; 2015 Dec; 6(41):43310-25. PubMed ID: 26621832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation.
    Chen JJ; Chou CW; Chang YF; Chen CC
    J Immunol; 2008 Jun; 180(12):8030-9. PubMed ID: 18523266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papillomavirus (HPV) 16 E6 sensitizes cells to atractyloside-induced apoptosis: role of p53, ICE-like proteases and the mitochondrial permeability transition.
    Brown J; Higo H; McKalip A; Herman B
    J Cell Biochem; 1997 Aug; 66(2):245-55. PubMed ID: 9213225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
    Seol DW
    Biochem Biophys Res Commun; 2011 Dec; 416(1-2):222-5. PubMed ID: 22120628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arsenic trioxide induces cervical cancer apoptosis, but specifically targets human papillomavirus-infected cell populations.
    Wen X; Li D; Zhang Y; Liu S; Ghali L; Iles RK
    Anticancer Drugs; 2012 Mar; 23(3):280-7. PubMed ID: 22245994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.
    Zhu H; Guo W; Zhang L; Wu S; Teraishi F; Davis JJ; Dong F; Fang B
    Cancer Biol Ther; 2005 Jul; 4(7):781-6. PubMed ID: 16082182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection.
    Clarke P; Meintzer SM; Spalding AC; Johnson GL; Tyler KL
    Oncogene; 2001 Oct; 20(47):6910-9. PubMed ID: 11687970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
    Sun SY; Yue P; Hong WK; Lotan R
    Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells.
    Li X; Huang T; Jiang G; Gong W; Qian H; Zou C
    Biochem Biophys Res Commun; 2013 Sep; 439(2):179-86. PubMed ID: 23994633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-beta in cervical carcinoma cells.
    Vannucchi S; Chiantore MV; Fiorucci G; Percario ZA; Leone S; Affabris E; Romeo G
    Oncogene; 2005 Apr; 24(15):2536-46. PubMed ID: 15735750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis.
    Yoshiba S; Iwase M; Kurihara S; Uchida M; Kurihara Y; Watanabe H; Shintani S
    Oncol Rep; 2011 Mar; 25(3):645-52. PubMed ID: 21206980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STAT3 activity regulates sensitivity to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cervical cancer cells.
    Nakamura H; Taguchi A; Kawana K; Kawata A; Yoshida M; Fujimoto A; Ogishima J; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Eguchi S; Mori-Uchino M; Yamashita A; Adachi K; Arimoto T; Wada-Hiraike O; Oda K; Nagamatsu T; Osuga Y; Fujii T
    Int J Oncol; 2016 Nov; 49(5):2155-2162. PubMed ID: 27599897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
    Duiker EW; de Vries EG; Mahalingam D; Meersma GJ; Boersma-van Ek W; Hollema H; Lub-de Hooge MN; van Dam GM; Cool RH; Quax WJ; Samali A; van der Zee AG; de Jong S
    Clin Cancer Res; 2009 Mar; 15(6):2048-57. PubMed ID: 19276284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant adenovirus-p53 gene transfer and cell-specific growth suppression of human cervical cancer cells in vitro and in vivo.
    Ahn WS; Bae SM; Lee KH; Lee JM; Namkoong SE; Chun HJ; Kim CK; Kim YW
    Gynecol Oncol; 2004 Feb; 92(2):611-21. PubMed ID: 14766255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
    Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S
    Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.